ORIGINAL ARTICLESProphylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer
References (18)
- et al.
Adenocarcinoma of the stomach: review of 1,497 cases
Cancer
(1978) - et al.
The surgical treatment of cancer of the stomach
Int Surg
(1980) - et al.
Absorption of water and crystalloid molecules from serous cavities
- et al.
Absorption of corpuscular particles from serous cavities
Mitomycin C adsorbed to activated carbon particles as a new drug dosage form for cancer chemotherapy [in Japanese]
Akita J Med
(1983)- et al.
Selective delivery of high levels of mitomycin C to peritoneal carcinomatosis using a new dosage form
Anticancer Res
(1986) - et al.
Chemotherapy for carcinomatous peritonitis with MMC-CH, mitomycin C adsorbed on activated carbon particles: clinical trials
Cancer
(1987) - et al.
Intraoperative chemotherapy with carbon particles adsorbing mitomycin C for gastric cancer with peritoneal dissemination in rabbits
Surgery
(1988)
Cited by (194)
Effect of intraperitoneal chemotherapy and peritoneal lavage in positive peritoneal cytology in gastric cancer. Systematic review and meta-analysis
2016, European Journal of Surgical OncologyCitation Excerpt :For discrete variables: Odd Ratio (OR) were calculated for peritoneal recurrence rate outcome, Risk Ratio (RR) were calculated for mortality outcome. The fixed-effects and random-effects models were used to calculate the outcomes.17,18 Heterogeneity amongst the trials was determined by means of the Cochrane Q value and quantified using the I2 inconsistency test.
Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cut-off. Systematic review and meta-analysis
2015, European Journal of Surgical OncologyIntraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials
2014, European Journal of Surgical OncologyCitation Excerpt :In the random-effects model, the 2-year mortality rate was significantly favourable to the surgery + IPC arm (OR = 0.16, 95%CI = 0.08–0.29). Three RCTs were included26,27,41 (Fig. 6). One study included patients with PC.27
Gastric Cancer
2011, Current Problems in CancerCitation Excerpt :After publication of the Intergroup 0116 data, 63.2% of potentially eligible patients did not receive chemoradiation therapy.39 Chemotherapy alone in the adjuvant setting has been studied in multiple trials using different agents, including mitomycin-c and anthracycline-based therapy, with some displaying survival benefit,40-54 and other studies not deriving benefit.55-61 Four meta-analyses62-65 of adjuvant chemotherapy vs surgery alone displayed conflicting results, with most negative, and the positive studies suffering from unusually low surgical control group survival.
Gastric cancer
2009, Critical Reviews in Oncology/HematologyMedicines for Cancer: Mechanism of Action and Clinical Pharmacology of Chemo, Hormonal, Targeted, and Immunotherapies
2023, Medicines for Cancer: Mechanism of Action and Clinical Pharmacology of Chemo, Hormonal, Targeted, and Immunotherapies